{"filing":{"accession_number":"0001193125-26-286825","cik":"0001590877","ticker":"RGNX","company_name":"REGENXBIO Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"rgnx-20260623.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526286825/rgnx-20260623.htm"},"events":[{"id":14457,"run_id":12870,"accession_number":"0001193125-26-286825","anchor_item_number":"8.01","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"REGENXBIO announced receipt of a $100 million milestone payment from AbbVie triggered by dosing the first patient in the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec. This is a material financial event—a substantial cash inflow tied to a contractual milestone under the September 2021 Collaboration and License Agreement. While the payment relates to clinical trial progress (operational), the primary disclosure centers on the financial obligation and cash receipt, making it a financial event rather than operational. It does not fit the specific categories of debt issuance, dividend distribution, or impairment, so financial_other is most appropriate.","company_name":"REGENXBIO Inc.","ticker":"RGNX","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":11902,"accession_number":"0001193125-26-286825","item_number":"8.01","item_title":"Other Events.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"REGENXBIO announced receipt of a $100 million milestone payment from AbbVie triggered by dosing the first patient in the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec. This is a material financial event—a substantial cash inflow tied to a contractual milestone under the September 2021 Collaboration and License Agreement. While the payment relates to clinical trial progress (operational), the primary disclosure centers on the financial obligation and cash receipt, making it a financial event rather than operational. It does not fit the specific categories of debt issuance, dividend distribution, or impairment, so financial_other is most appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:16:38.292678+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11902,"accession_number":"0001193125-26-286825","item_number":"8.01","item_title":"Other Events.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"REGENXBIO announced receipt of a $100 million milestone payment from AbbVie triggered by dosing the first patient in the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec. This is a material financial event—a substantial cash inflow tied to a contractual milestone under the September 2021 Collaboration and License Agreement. While the payment relates to clinical trial progress (operational), the primary disclosure centers on the financial obligation and cash receipt, making it a financial event rather than operational. It does not fit the specific categories of debt issuance, dividend distribution, or impairment, so financial_other is most appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:16:38.292678+00:00","company_name":"REGENXBIO Inc.","ticker":"RGNX","filing_date":"2026-06-29"}]}